MedWatch

FDA agrees to meeting with Enochian over HIV therapy

The US authority has said yes to a meeting with Enochian Biosciences to discuss a potential start to clinical trials of the company's HIV treatment. The biotech company is also looking to raise funds.

Photo: Andrew Kelly/REUTERS / X02844

Enochian Biosciences has secured a meeting with the US Food and Drug Administration (FDA). This means the company is sticking to its previously announced schedule, which predicted discussions with the authority would start in 2021.

The meeting is a so-called pre-IND meeting, which companies must attend before starting clinical trials in the US. The subject of the meeting is Enochian's HIV therapy, which in the company's own words, could potentially be a "functional cure" for the disease.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs